findmyKOL
Clinical trialNCT03862157Active, not recruitingPhase 1/PHASE2Interventional

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

SponsorM.D. Anderson Cancer CenterEnrollment40Acute Myeloid LeukemiaAtypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeChronic Eosinophilic Leukemia, Not Otherwise SpecifiedChronic Myelomonocytic LeukemiaChronic Neutrophilic LeukemiaEssential Thrombocythemia+10 more conditions
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • M D Anderson Cancer Center

    Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Azacitidine →PevonedistatVenetoclax →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
27 Feb 2019
Primary completion
31 Jan 2027
Completion
31 Jan 2027
Last update posted
11 Mar 2026
Registered enrollment
40
Registry id
NCT03862157
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.